SCHEMBL1429969

SCHEMBL1429969

COC(=O)c1cccc(-c2nc(-c3ccc(OC)cc3)no2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.63
NR1H4 Q96RI1 1/20 0.63
NPC1 O15118 4/20 0.61
RAB9A P51151 3/20 0.61
KMT2A Q03164 3/20 0.61
MAPT P10636 2/20 0.61
HSD17B10 Q99714 2/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2C19 P33261 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
SMN1; SMN2 Q16637 2/20 0.60
TP53 P04637 1/20 0.60
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
HAVCR2 Q8TDQ0 10/20 0.60
ALDH1A1 P00352 1/20 0.59
POLB P06746 1/20 0.57
KDM4E B2RXH2 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19131023 0.90 NPC1 (0.70) S1PR1NR1H4NPC1RAB9AKMT2A
SCHEMBL1430178 0.89 NR1H4 (0.68) S1PR1NR1H4NPC1RAB9AKMT2A
SCHEMBL4875219 0.88 NPC1 (0.67) S1PR1NPC1RAB9AKMT2AMAPT
SCHEMBL19131014 0.86 S1PR1 (0.58) S1PR1NPC1RAB9AKMT2AMAPT
SCHEMBL19132173 0.85 NPC1 (0.58) S1PR1NR1H4NPC1RAB9AKMT2A
SCHEMBL13427330 0.84 NPC1 (0.73) S1PR1NR1H4NPC1RAB9AKMT2A
SCHEMBL60692 0.84 NR1H4 (0.68) S1PR1NR1H4NPC1RAB9AKMT2A
SCHEMBL19131267 0.83 S1PR1 (0.57) S1PR1NPC1RAB9AKMT2AMAPT
SCHEMBL12692350 0.83 NPC1 (0.86) S1PR1NR1H4NPC1RAB9AKMT2A
SCHEMBL12171803 0.82 NPC1 (0.65) NPC1RAB9AKMT2AMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130096165-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2013-04-18 US disclosed
US-20130096165-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2013-04-18 US disclosed
US-8362050-B2 Compounds and methods for modulating G protein-coupled receptors IRM LLC (BM) 2013-01-29 US disclosed
US-8362050-B2 Compounds and methods for modulating G protein-coupled receptors IRM LLC (BM) 2013-01-29 US disclosed
US-20110172278-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2011-07-14 US disclosed
US-20110172278-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2011-07-14 US disclosed
EP-2300442-A2 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2011-03-30 EP disclosed
WO-2010008831-A2 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096165-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS GRK2, GRK3, GPR3 S1PR1 512/4885NR1H4 150/4885NPC1 856/4885
US-20110172278-A1 COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS GRK2, GRK3, GPR3 S1PR1 512/4885NR1H4 150/4885NPC1 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.